Description
The HOYA iSert 251 Monofocal Preloaded Intraocular Lens (IOL) is a sophisticated solution designed for cataract surgery, offering precision and ease of use. This lens is part of HOYA's advanced line of intraocular lenses, renowned for enhancing visual outcomes and surgical efficiency.
Advanced Optic Design
Crafted from hydrophobic acrylic, the lens features an aspheric, aberration-correcting design that provides sharp and clear vision. Its 6.0 mm optic diameter and sharp edge design help minimize posterior capsule opacification, ensuring long-term clarity. Integrated UV and blue light filters offer additional protection, making it a comprehensive choice for eye care.
Innovative Haptic Configuration
The lens includes a modified C-loop haptic design with chemically bonded blue PMMA tips, ensuring stable positioning within the eye. With an overall length of 12.5 mm and a 5° angulation, it is engineered for optimal alignment and performance.
Preloaded Injector System
The iSert preloaded injector system is a standout feature, eliminating the need for manual lens handling. This system enhances safety and efficiency by reducing the risk of lens damage and ensuring smooth delivery through small incisions. Compatible with a 2.4 mm incision, it is designed for precise and predictable implantation.
Power Range and Biometry
Available in powers ranging from +6.00 D to +30.00 D in 0.50 D increments, the lens accommodates a wide range of visual needs. It provides optimized constants for various biometric formulas, supporting accurate surgical planning.
Regulatory Approvals and Global Reach
The HOYA iSert 251 is CE marked and FDA approved, reflecting its adherence to high-quality standards. Widely available across the USA, Japan, EMEA, and APAC regions, it is part of a trusted series with a proven track record.
Proven Material and Clinical Success
With over 10 million IOLs using this material sold worldwide, the lens boasts a history of reliability and success. It is designed to enhance surgical workflow, reduce risks, and improve patient outcomes, making it an ideal choice for ophthalmic surgeons globally.
